A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 261 participants.

Also called NCT04736628

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 261 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04736628
  • EudraCT 2020-002930-33
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Canada, China, Denmark, Germany, Hong Kong SAR China, Japan, Malaysia, Mexico, New Zealand, Poland, Portugal, Russia, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04736628. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-27 (actual); primary completion 2023-08-15 (actual). Results posted on 2024-09-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
Intervention (Drug)
Avenciguat
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct04736628
Content hash
832a358f83f3b6f194110dd41f9c12f01cbcb2b9a6b62373776978f4a8317490